Crohn’s Candidates Capitalize On TNF Inhibitor Risks At DDW Meeting
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Ocera Therapeutics is going against the tide of biologics for Crohn’s disease as its adsorptive carbon agent AST-120 enters Phase III in fistulizing Crohn’s disease.
You may also be interested in...
NPS Seeks Development Partners For Preos And Teduglutide, Reduces Force
NPS Pharmaceuticals is reducing its workforce and consolidating operations while continuing to advance two pipeline candidates - the osteoporosis agent Preos and the gastrointestinal treatment teduglutide -following a review of its financial situation
Approvals In Brief
Abbott’s Humira gains ankylosing spondylitis claim, putting agent in closer competition with Amgen’s Enbrel and Johnson & Johnson/Centocor’s Remicade. Shire’s Elaprase (idursulfase) is first enzyme replacement therapy approved for Hunter syndrome. More approvals in brief
UCB’s Cimzia BLA Could Provide First Subcutaneous Injection For Crohn’s
UCB is touting the "greater convenience" of its Cimzia subcutaneous injection for Crohn's disease compared to Johnson & Johnson's intravenous injection Remicade